181 related articles for article (PubMed ID: 36573186)
1. Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: A systematic review.
Philip LJ; Findlay SG; Gill JH
Int J Cardiol Cardiovasc Risk Prev; 2022 Dec; 15():200153. PubMed ID: 36573186
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
3. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
4. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
5. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
6. Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.
Kotwinski P; Smith G; Cooper J; Sanders J; Ma L; Teis A; Kotwinski D; Mythen M; Pennell DJ; Jones A; Montgomery H;
PLoS One; 2016; 11(12):e0165262. PubMed ID: 27911951
[TBL] [Abstract][Full Text] [Related]
7. Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography.
Zhao R; Shu F; Zhang C; Song F; Xu Y; Guo Y; Xue K; Lin J; Shu X; Hsi DH; Cheng L
JACC CardioOncol; 2020 Mar; 2(1):13-22. PubMed ID: 34396205
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
9. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
10. Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.
Díaz-Antón B; Madurga R; Zorita B; Wasniewski S; Moreno-Arciniegas A; López-Melgar B; Ramírez Merino N; Martín-Asenjo R; Barrio P; Amado Escañuela MG; Solís J; Parra Jiménez FJ; Ciruelos E; Castellano JM; Fernández-Friera L
ESC Heart Fail; 2022 Apr; 9(2):1127-1137. PubMed ID: 35106939
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients from Southern Sri Lanka: An Echocardiographic Analysis.
Sandamali JAN; Hewawasam RP; Fernando MACSS; Jayatilaka KAPW; Madurawe RD; Sathananthan PP; Ekanayake U; Horadugoda J
Biomed Res Int; 2020; 2020():1847159. PubMed ID: 33274195
[TBL] [Abstract][Full Text] [Related]
12. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
13. Two-dimensional speckle tracking echocardiography predicts early subclinical cardiotoxicity associated with anthracycline-trastuzumab chemotherapy in patients with breast cancer.
Arciniegas Calle MC; Sandhu NP; Xia H; Cha SS; Pellikka PA; Ye Z; Herrmann J; Villarraga HR
BMC Cancer; 2018 Oct; 18(1):1037. PubMed ID: 30359235
[TBL] [Abstract][Full Text] [Related]
14. Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis.
Jin H; Xu J; Sui Z; Wang L
Front Cardiovasc Med; 2023; 10():1101585. PubMed ID: 36742068
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
[TBL] [Abstract][Full Text] [Related]
16. Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.
Hamirani Y; Fanous I; Kramer CM; Wong A; Salerno M; Dillon P
Med Oncol; 2016 Jul; 33(7):82. PubMed ID: 27334792
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
18. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Clarke JL; Thomas L
Eur Heart J Cardiovasc Imaging; 2013 Mar; 14(3):228-34. PubMed ID: 22782955
[TBL] [Abstract][Full Text] [Related]
19. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]